WCN26-6573 SOLUBLE BIOMARKERS IN IgA NEPHROPATHY: ANALYSIS OF BASELINE DATA FROM THE PHASE 2 TRIAL OF RAVULIZUMAB (SANCTUARY)

Read full text Summarise with VIRAT
Authors: Jonathan Barratt, Tobin J. Cammett, Ellen E. Millman, Julio C. Luna, Kara Creamer Rice, Katherine G. Garlo, Andreas K. Kateifides, STEPHEN T. NOLAN, Cory Williams, Richard A. Lafayette, Youssef M.K. Farag
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In IgA nephropathy (IgAN), immune complex formation and deposition leads to complement activation, culminating in complement terminal pathway-mediated inflammation and kidney damage. Validated soluble biomarkers of disease activity and pathophysiology are needed in IgAN. This analysis aimed to characterize biomarkers using baseline data from the Phase 2 trial (NCT04564339) of ravulizumab (RAV) (a complement C5 inhibitor) and from healthy adult normal donors (ND).

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Complement system in diseases Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104503–104503
Publication date
25 March 2026
Language
EN